Investigation of possible teratogenic effects in the offspring of @entity19 exposed to XXXX during pregnancy.

@entity1 @entity19 @entity600 @entity7541 @entity148 @entity2727
UNASSIGNED: @entity2727 ( @entity7541 ) is a central nervous system stimulant drug that increases concentration and energy level. The safety of @entity7541 use during pregnancy is not well established. Considering the high rate of unplanned pregnancy among young @entity1 , potential for accidental exposure to @entity7541 in early pregnancy is high. This study aimed to investigate if @entity7541 administered during pregnancy would induce maternotoxicity, teratogenicity in @entity19 , or both. Pregnant Swiss @entity19 were treated with @entity7541 (5   mg/kg, subcutaneously) or 0.9% saline (control group) from the 5th to the 17th day of pregnancy. In the @entity7541 -treated group, a significant increase in the total number of resorptions with a consequent increase in post-implantation loss and a decrease in fetal viability were detected (all P < 0.05). A total of 91.43% of resorptions were classified as early resorptions. The group treated with @entity7541 presented significant external (polydactyly P < 0.01), skeletal (incomplete ossification of the skull P < 0.01) and visceral (dilated ventricles P < 0.05) @entity600 . Behavioural effects (motor activity, memory of habituation and @entity148 ) were not observed in both male and female offspring evaluated at postnatal days 22, 35 and 75. The results suggest that @entity7541 is an embryotoxic and teratogenic drug.
